依达拉奉对帕金森病的疗效观察

Curative effect observation of Edaravone in Parkinson disease

目的 研究依达拉奉治疗早、晚期帕金森病（PD）的临床效果。方法 选择2015年4月~2016年4月在我院治疗的36例PD患者,将患者按病程分为早期PD组（≤3.5年）和晚期PD组（≥4年）。在常规PD治疗的基础上,给予依达拉奉30 mg,加入250 ml 0.9%氯化钠溶液中静脉滴注,2次/d,连续应用2周。应用PD统一评分量表（UPDRS）评价治疗效果,并观察不良反应发生情况,同时检测与比较两组治疗前后的血清Aβ1-42、BDNF。结果 治疗后,早期PD组在日常生活活动,精神活动、行为和精神,运动检查三个方面的UPDRS评分均较治疗前显著降低（P〈0.05）;晚期PD组治疗前后上述指标评分比较差异无统计学意义（P〉0.05）。早期PD组治疗后的血清Aβ1-42、BDNF则高于晚期PD组（P〈0.05）。36例患者中,有3例（8.33%）出现肝功能异常、皮疹等不良反应,但均较轻微,对症治疗后恢复正常。结论 依达拉奉对改善早期PD患者的病情具有明显效果,但对晚期PD的效果不明显。

Objective To study the clinical effect of Edaravone treating Parkinson disease （PD） of early and late stage. Methods 36 patients with treated by our hospital from April 2015 to April 2016 were selected,and they were divided into PD of early stage group （-〈-3.5 years） and PD of late stage group （/〉4 years）.Patients were treated by Edaravone of 30 mg added into 250 ml of 0.9% sodium chloride solution to intravenously drip for 2 times every day on the basis of the routine PD treatment,and drugs were used for 2 weeks.The unified rating scale of PD （UPDRS） was used to evaluate the curative effect after treatment,incidence of complications was observed,and serum AI3t-42 and BDNF between two groups before and after treatment were detected and compared.Results After treatment,mental activity,behavior and mind,daily living activity and motor examination of the UPDRS score in PD of early stage group were significantly decreased compared with before treatment （P〈0.05）,while there was no significant differences of above-mentioned indexes in PD of late stage group before and after treatment （P〉0.05）.The serum Aβ1-42and BDNF of PD of early stage group after treatment were higher than those of PD of late stage group （P〈0.05）.In 36 cases,3 cases （8.33%） had abnormal liver function,rash and other adverse reactions,but all were mild,and recovered to normal after symptomatic treatment. Conclusion Edaravone has obvious effect to improve the condition of patients with PD in early stage,but the effect is not obvious in patients with PD in late stage.